Genetic disruption of the oncogenic HMGA2-PLAG1-IGF2 pathway causes fetal growth restriction

Genetics in Medicine

Volumn 20, Issue 2, 2018, Pages 250-258

  Habib, Walid Abi ^a,b,j   Brioude, Frédéric ^a,b   Edouard, Thomas ^c,d   Bennett, James T ^e   Lienhardt Roussie, Anne ^f   Tixier, Frédérique ^g   Salem, Jennifer ^h   Yuen, Tony ⁱ   Azzi, Salah ^a,b   Le Bouc, Yves ^a,b   Harbison, Madeleine D ⁱ   Netchine, Irène ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d University of Toulouse III   (France)

^e UNIVERSITY OF WASHINGTON   (United States)

^f LIMOGES UNIVERSITY HOSPITAL   (France)

^g HÔPITAL DEBROUSSE   (France)

^h MAGIC Foundation   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j VAN ANDEL RESEARCH INSTITUTE   (United States)

more..

Author keywords

Fetal growth restriction; HMGA2; IGF2; PLAG1; Silver russell syndrome

Indexed keywords

SMALL INTERFERING RNA; DNA BINDING PROTEIN; HIGH MOBILITY GROUP A2 PROTEIN; IGF2 PROTEIN, HUMAN; PLAG1 PROTEIN, HUMAN; SOMATOMEDIN B;

ARTICLE; CHILD; CHROMOSOME 11; CHROMOSOME 14; CHROMOSOME 7; DOWN REGULATION; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENE DISRUPTION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC VARIATION; HEK293 CELL LINE; HETEROZYGOSITY; HMGA2 GENE; HUMAN; IGF2 GENE; INFANT; MACROCEPHALY; MAJOR CLINICAL STUDY; NONHUMAN; NONSENSE MUTATION; ONCOGENE; PLAG1 GENE; SILVER RUSSELL SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; WHOLE EXOME SEQUENCING; BIOLOGICAL MODEL; CELL LINE; FACIES; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDY; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; GROWTH CHART; INTRAUTERINE GROWTH RETARDATION; METABOLISM; MUTATION; PEDIGREE; SIGNAL TRANSDUCTION; WHOLE GENOME SEQUENCING;

CELL LINE; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; FACIES; FEMALE; FETAL GROWTH RETARDATION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; GROWTH CHARTS; HMGA2 PROTEIN; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MODELS, BIOLOGICAL; MUTATION; PEDIGREE; SIGNAL TRANSDUCTION; SILVER-RUSSELL SYNDROME; WHOLE GENOME SEQUENCING;

EID: 85041513572     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2017.105     Document Type: Article

References (37)

1. Sheridan C. Intrauterine growth restriction-diagnosis and management. Aust Fam Physician. 2005;34:717-723.
2. Azzi S, Salem J, Thibaud N, et al. A prospective study validating a clinical scoring system and demonstrating phenotypical-genotypical correlations in Silver-Russell syndrome. J Med Genet. 2015;52:446-453.
3. Dias RP, Nightingale P, Hardy C, et al. Comparison of the clinical scoring systems in Silver-Russell syndrome and development of modified diagnostic criteria to guide molecular genetic testing. J Med Genet. 2013;50:635-639.
4. Bartholdi D, Krajewska-Walasek M, Ounap K, et al. Epigenetic mutations of the imprinted IGF2-H19 domain in Silver-Russell syndrome (SRS): Results from a large cohort of patients with SRS and SRS-like phenotypes. J Med Genet. 2009;46:192-197.
5. Netchine I, Rossignol S, Dufourg MN, et al. 11p15 imprinting center region 1 loss of methylation is a common and specific cause of typical Russell-Silver syndrome: clinical scoring system and epigeneticphenotypic correlations. J Clin Endocrinol Metab. 2007;92:3148-3154.
6. Wakeling EL, Brioude F, Lokulo-Sodipe O, et al. Diagnosis and management of Silver-Russell syndrome: first international consensus statement. Nat Rev Endocrinol. 2016;13:105-124.
7. Gicquel C, Rossignol S, Cabrol S, et al. Epimutation of the telomeric imprinting center region on chromosome 11p15 in Silver-Russell syndrome. Nat Genet. 2005;37:1003-1007.
8. Azzi S, Blaise A, Steunou V, et al. Complex tissue-specific epigenotypes in Russell-Silver Syndrome associated with 11p15 ICR1 hypomethylation. Hum Mutat. 2014;35:1211-1220.
9. Brioude F, Oliver-Petit I, Blaise A, et al. CDKN1C mutation affecting the PCNA-binding domain as a cause of familial Russell Silver syndrome. J Med Genet. 2013;50:823-830.
10. Begemann M, Zirn B, Santen G, et al. Paternally inherited IGF2 mutation and growth restriction. N Engl J Med. 2015;373:349-356.
11. Kas K, Voz ML, Roijer E, et al. Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations. Nat Genet. 1997;15:170-174.
12. Astrom A, D'Amore ES, Sainati L, et al. Evidence of involvement of the PLAG1 gene in lipoblastomas. Int J Oncol. 2000;16:1107-1110.
13. Zatkova A, Rouillard JM, Hartmann W, et al. Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma. Genes Chromosomes Cancer. 2004;39:126-137.
14. Voz ML, Agten NS, Van de Ven WJ, Kas K. PLAG1, the main translocation target in pleomorphic adenoma of the salivary glands, is a positive regulator of IGF-II. Cancer Res. 2000;60:106-113.
15. Hensen K, Van Valckenborgh IC, Kas K, Van de Ven WJ, Voz ML. The tumorigenic diversity of the three PLAG family members is associated with different DNA binding capacities. Cancer Res. 2002;62:1510-1517.
16. Declercq J, Van Dyck F, Braem CV, et al. Salivary gland tumors in transgenic mice with targeted PLAG1 proto-oncogene overexpression. Cancer Res. 2005;65:4544-4553.
17. Hensen K, Braem C, Declercq J, et al. Targeted disruption of the murine Plag1 proto-oncogene causes growth retard ation and reduced fertility. Dev Growth Differ. 2004;46:459-470.
18. Klemke M, Muller MH, Wosniok W, et al. Correlated expression of HMGA2 and PLAG1 in thyroid tumors, uterine leiomyomas and experimental models. PLoS One. 2014;9:e88126.
19. Zhou X, Benson KF, Ashar HR, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGIC. Nature. 1995;376:771-774.
20. De Crescenzo A, Citro V, Freschi A, et al. A splicing mutation of the HMGA2 gene is associated with Silver-Russell syndrome phenotype. J Hum Genet. 2015;60:287-293 .
21. Fokstuen S, Kotzot D. Chromosomal rearrangements in patients with clinical features of Silver-Russell syndrome. Am J Med Genet A. 2014;164A:1595-1605.
22. Okada Y, Kamatani Y, Takahashi A, et al. A genome-wide association study in 19 633 Japanese subjects identified LHX3-QSOX2 and IGF1 as adult height loci. Hum Mol Genet. 2010;19:2303-2312.
23. Cho YS, Go MJ, Kim YJ, et al. A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat Genet. 2009;41:527-534.
24. Gudbjartsson DF, Walters GB, Thorleifsson G, et al. Many sequence variants affecting diversity of adult human height. Nat Genet. 2008;40: 609-615.
25. Weedon MN, Lettre G, Freathy RM, et al. A common variant of HMGA2 is associated with adult and childhood height in the general population. Nat Genet. 2007;39:1245-1250.
26. Chinuck R, Dewar J, Baldwin DR, Hendron E. Appetite stimulants for people with cystic fibrosis. Cochrane Database Syst Rev. 2014: CD008190.
27. Chao W, D'Amore PA. IGF2: Epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev. 2008;19:111-120.
28. Abi Habib W, Brioude F, Azzi S, et al. 11p15 ICR1 partial deletions associated with IGF2/H19 DMR hypomethylation and Silver-Russell syndrome. Hum Mutat. 2016;38:105-111.
29. Abi Habib W, Azzi S, Brioude F, et al. Extensive investigation of the IGF2/H19 imprinting control region reveals novel OCT4/SOX2 binding site defects associated with specific methylation patterns in Beckwith- Wiedemann syndrome. Hum Mol Genet. 2014;23:5763-5773.
30. Azzi S, Abi Habib W, Netchine I. Beckwith-Wiedemann and Russell-Silver Syndromes: from new molecular insights to the comprehension of imprinting regulation. Curr Opin Endocrinol Diabetes Obes. 2014;21: 30-38.
31. Mott R, Yuan W, Kaisaki P, et al. The architecture of parent-of-origin effects in mice. Cell. 2014;156:332-342.
32. Juma AR, Damdimopoulou PE, Grommen SV, Van de Ven WJ, De Groef B. Emerging role of PLAG1 as a regulator of growth and reproduction. J Endocrinol. 2016;228:R45-R56.
33. DeChiara TM, Efstratiadis A, Robertson EJ. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature. 1990;345:78-80.
34. Akhtar M, Holmgren C, Gondor A, et al. Cell type and context-specific function of PLAG1 for IGF2 P3 promoter activity. Int J Oncol. 2012;41: 1959-1966.
35. Li X, Nong Z, Ekstrom C, et al. Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res. 1997;57:2048-2054.
36. Ekstrom TJ, Cui H, Li X, Ohlsson R. Promoter-specific IGF2 imprinting status and its plasticity during human liver development. Development. 1995;121:309-316.
37. Gnirke A, Melnikov A, Maguire J, et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol. 2009;27:182-189.